China Botanic Pharmaceutical Inc.
CBPI
Other OTC0.07
USD
+0.01
- -
CIK
0000926844
ISIN
US16890Y1047
CUSIP
16890Y104
Return %
Stock
S&P500
1Y
-95.71
18.21
3Y
2,516.39
64.38
5Y
2,516.39
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1185 Avenue of the Americas New York City NY United States of America 10004
- IPO Date
- Mar 27, 2000
- CIK
- 0000926844
- Similar Companies
- Business
- Fuss Brands Corp., formerly known as China Botanic Pharmaceutical Inc., operates as a non-operating entity seeking business opportunities in the United States, including potential acquisitions through reverse mergers or asset purchases; it maintains no significant current operations or revenue-generating activities. Originally incorporated in Nevada in 1988 under various prior names, including Renhuang Pharmaceuticals, Inc. from 2006 and China Botanic Pharmaceutical Inc. from 2010, the company ceased pharmaceutical activities in China after September 2012 and shifted focus following custodianship proceedings in 2021; headquarters reside at 80 Broad Street, New York, New York. Historically engaged in the research, development, manufacture, and distribution of botanical products, bio-pharmaceuticals, and traditional Chinese medicines from facilities in Harbin, China—including botanical anti-depression and nerve-regulation products (accounting for approximately 70% of fiscal 2011 revenues), biopharmaceuticals, botanical antibiotics, and over-the-counter traditional medicines—the company produced over 200 products across 18 dosage forms prior to dormancy. In July 2022, the company amended its articles of incorporation to effect a 1-for-26 reverse stock split and change its name to Fuss Brands Corp., with FINRA approving the updates and assigning the ticker FBDS shortly thereafter; this rebranding anticipated entry into new business lines, diverging from its prior pharmaceutical focus. Leadership transitions include the 2021 custodianship appointment of David Lazar as CEO followed by control acquisition via Series A-1 Preferred Stock transfer to new shareholders, Issamar Ginzberg's appointment as CEO, and his resignation in January 2024 alongside Cheskel Meisels' election as Chairman and CEO; in August 2025, the company dismissed auditor Olayinka Oyebola & Co. and engaged LAO Professionals without reported disagreements. A January 2023 purchase order for $925,000 in luggage from a leading retailer marked an initial step toward operations, though fulfillment remains in process with a manufacturer; the company explores ventures amid competitive pressures from venture capital and blank check entities. Geographically, prior operations centered in the People's Republic of China with headquarters historically in Harbin, while current efforts target U.S.-based opportunities under Nevada incorporation.